Skip to content

Study · Randomized controlled trial · 2020

7 results

Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.

Zhang LY, Qu XN, Sun ZY, Zhang Y

Clinics and research in hepatology and gastroenterology26 Feb 2020Cited by 63 (Europe PMC)

PMID32113823 (opens in a new tab)DOI10.1016/j.clinre.2020.01.007 (opens in a new tab)PepBankPUB-32113823
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and fatty liver disease, serum fetuin-A fell after 24 weeks of liraglutide.

    In plain wordsIn adults with type 2 diabetes and fatty liver disease, liraglutide lowered blood fetuin-A levels over 24 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseSerum fetuin-A
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Fetuin-A
    443.7 μg/mL
    liraglutide after 24 weeks

    Source sentences

    Summary
    In the liraglutide group, fetuin-A levels decreased after 24 weeks (666.1±109.4 vs. 443.7±90.5μg/mL, P<0.05).
    1 context sentence
    Summary · context
    Sixty patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease were randomly assigned to the liraglutide and pioglitazone groups on a 1:1 basis using a computer-generated sequence.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and fatty liver disease, fetuin-A fell more with liraglutide than with pioglitazone after 24 weeks.

    In plain wordsIn adults with type 2 diabetes and fatty liver disease, liraglutide lowered fetuin-A more than pioglitazone did.

    Peptide
    Liraglutide
    Outcome
    DecreaseSerum fetuin-A versus pioglitazone
    Study

    n: not reported in source

    Comparator
    Pioglitazone
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    In the pioglitazone group, fetuin-A levels also decreased after 24 weeks (659.3±111.8 vs. 538.1± 101.0μg/mL, P<0.05) but not to the level of the liraglutide group.
    2 context sentences
    Summary · context
    Liraglutide treatment resulted in a decrease in hepatic fat content and fetuin-A compared with pioglitazone treatment in patients with T2DM and NAFLD.
    Summary · context
    Sixty patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease were randomly assigned to the liraglutide and pioglitazone groups on a 1:1 basis using a computer-generated sequence.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and fatty liver disease, liver fat measured by 1H-MRS fell after 24 weeks of liraglutide.

    In plain wordsIn adults with type 2 diabetes and fatty liver disease, liraglutide reduced liver fat over 24 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseHepatic fat content (1H-MRS)
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    The liraglutide treatment resulted in a decrease in 1H-MRS (24.1±3.0 vs. 20.1±3.8, P<0.05).
    1 context sentence
    Summary · context
    Sixty patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease were randomly assigned to the liraglutide and pioglitazone groups on a 1:1 basis using a computer-generated sequence.
  4. 04HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes and fatty liver disease on liraglutide, the change in fetuin-A correlated positively with the change in weight.

    In plain wordsIn adults on liraglutide, bigger drops in fetuin-A went with bigger weight loss. This shows a link, not a cause.

    Peptide
    Liraglutide
    Outcome
    Not applicableCorrelation of change in fetuin-A with change in weight
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    ΔFetuin-A was positively correlated with Δweight (r=0.756, P=0.035)
    1 context sentence
    Summary · context
    Sixty patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease were randomly assigned to the liraglutide and pioglitazone groups on a 1:1 basis using a computer-generated sequence.
  5. 05HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes and fatty liver disease on liraglutide, the change in fetuin-A correlated positively with the change in BMI.

    In plain wordsIn adults on liraglutide, bigger drops in fetuin-A went with bigger drops in BMI. This shows a link, not a cause.

    Peptide
    Liraglutide
    Outcome
    Not applicableCorrelation of change in fetuin-A with change in BMI
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    ΔFetuin-A was positively correlated with Δweight (r=0.756, P=0.035), ΔBMI (r=0.653, P=0.006)
    1 context sentence
    Summary · context
    Sixty patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease were randomly assigned to the liraglutide and pioglitazone groups on a 1:1 basis using a computer-generated sequence.
  6. 06HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes and fatty liver disease on liraglutide, the change in fetuin-A correlated positively with the change in waist circumference.

    In plain wordsIn adults on liraglutide, bigger drops in fetuin-A went with bigger drops in waist size. This shows a link, not a cause.

    Peptide
    Liraglutide
    Outcome
    Not applicableCorrelation of change in fetuin-A with change in waist circumference
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    ΔFetuin-A was positively correlated with Δweight (r=0.756, P=0.035), ΔBMI (r=0.653, P=0.006), Δwaist circumference (r=0.767, P=0.010)
    1 context sentence
    Summary · context
    Sixty patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease were randomly assigned to the liraglutide and pioglitazone groups on a 1:1 basis using a computer-generated sequence.
  7. 07HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes and fatty liver disease on liraglutide, the change in fetuin-A correlated positively with the change in hepatic fat content.

    In plain wordsIn adults on liraglutide, bigger drops in fetuin-A went with bigger drops in liver fat. This shows a link, not a cause.

    Peptide
    Liraglutide
    Outcome
    Not applicableCorrelation of change in fetuin-A with change in hepatic fat (1H-MRS)
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    ΔFetuin-A was positively correlated with Δweight (r=0.756, P=0.035), ΔBMI (r=0.653, P=0.006), Δwaist circumference (r=0.767, P=0.010), and Δ1H-MRS (r=0.732, P=0.004)
    1 context sentence
    Summary · context
    Sixty patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease were randomly assigned to the liraglutide and pioglitazone groups on a 1:1 basis using a computer-generated sequence.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.